Technical Data
T9160-41
Tumor Necrosis Factor beta, Recombinant, Human (TNFb)
5ug
20ug
20ug
|
Technical Data |
|
T9160-41 |
Tumor Necrosis Factor beta, Recombinant, Human (TNFb) |
5ug 20ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
Recombinant Human TNF-beta (Lymphotoxin) is a single, non-glycosylated, polypeptide chain containing 171 amino acids and having a molecular mass of 18645 Dalton. Recombinant Human Tumor Necrosis Factor-beta is purified by standard chromatographic techniques. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Met-Val-Arg-Ser-Ser. Dimers and Aggregates: 1% as determined by silver-stained SDS-PAGE gel analysis. Biological Activity: TNF-beta is fully biologically active when compared to standard. The ED50 as determined by the cytolysis of murine L929 cells in the presence of Actinomycin D is less then 0.05ng/ml, corresponding to a Specific Activity of 2 x10e6 IU/mg. Endotoxin: 0.1ng/ug (IEU/ug) of TNF-beta. Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 1.082 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of TNF-beta as a Reference Standard. Reconstitution: Reconstitute the lyophilized TNF-beta in sterile 18M-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions. Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. |
Source: E. coli Purity: 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Concentration: ~0.1mg/ml Form: Supplied as a lyophilized powder. No additives. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Polymorphisms within the genes encoding TNF-alpha and TNF-beta associate with the incidence of post-transplant complications in recipients of allogeneic hematopoietic stem cell transplants. Bogunia-Kubik K, Arch Immunol Ther Exp (Warsz) 2004 Jul-Aug;52(4):240-9 2. Are postoperative complications genetically determined by TNF-beta NcoI gene polymorphism? Kahlke V, Schafmayer C, Seegert D, Surgery 2004 Apr;135(4):365-73; discussion 374-5 3. Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus. Goyal A, Kazim SN, Malhotra V, J Med Virol 2004 Jan;72(1):60-5 4. TNF-alpha and TNF-beta gene polymorphisms in cerebral infarction. Um JY, An NH, J Mol Neurosci 2003;21(2):167-71 5. Serum levels of TNF-beta and sTNF-R in patients with malignant bone tumours. Holzer G, Pfandlsteiner T, Trieb K, Anticancer Res 2003 May-Jun;23(3C):3057-9 6. Influence of the TNF-alpha and TNF-beta polymorphisms upon infectious risk and outcome in surgical intensive care patients. Calvano JE, Um JY, Hahm SJ, Lowry SF, Surg Infect (Larchmt) 2003 Summer;4(2):163-9.
|
||